^
Association details:
| Biomarker: | CD200 underexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD200/CD200R protein expression in primary melanomas of patients who underwent treatment with immune checkpoint inhibitors: preliminary results
Published date:
04/20/2023
Excerpt:
We analyzed immunohistochemically the expression of CD200/CD200R in tissue samples of 33 advanced melanoma patients in non-resectable stage III or IV and correlated our findings with the treatment response to initial immunotherapy using ICI (ipilimumab, nivolumab, pembrolizumab)....Univariate analysis revealed that female gender and lower intra-tumoral CD200 expression were significantly associated with response to ICI.
